Kymera Therapeutics (KYMR) Projected to Post Quarterly Earnings on Thursday

Kymera Therapeutics (NASDAQ:KYMR) is anticipated to issue its Q1 2026 results before the market opens on Thursday, April 30th. Analysts expect the company to announce earnings of ($0.89) per share and revenue of $8.2670 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, April 30, 2026 at 8:30 AM ET.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The company had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. During the same period in the prior year, the company posted ($0.88) EPS. The firm’s revenue was down 60.8% compared to the same quarter last year. On average, analysts expect Kymera Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock traded down $3.61 during trading hours on Wednesday, reaching $80.24. 114,175 shares of the company were exchanged, compared to its average volume of 697,275. Kymera Therapeutics has a 1 year low of $28.06 and a 1 year high of $103.00. The stock’s fifty day moving average is $84.70 and its 200 day moving average is $76.16. The firm has a market cap of $6.55 billion, a PE ratio of -21.80 and a beta of 2.28.

Analyst Ratings Changes

KYMR has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. Piper Sandler upped their price objective on Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. BTIG Research cut their price objective on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Stephens increased their target price on Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Monday, March 2nd. Finally, Barclays increased their target price on Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a report on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $118.90.

Insider Transactions at Kymera Therapeutics

In related news, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $90.26, for a total value of $2,707,800.00. Following the transaction, the chief executive officer owned 666,195 shares of the company’s stock, valued at $60,130,760.70. This represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Noah Goodman sold 8,264 shares of the stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $87.50, for a total value of $723,100.00. Following the completion of the transaction, the insider directly owned 53,542 shares in the company, valued at $4,684,925. This trade represents a 13.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 350,734 shares of company stock valued at $29,758,502 over the last ninety days. Company insiders own 16.01% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds have recently made changes to their positions in KYMR. Price T Rowe Associates Inc. MD grew its holdings in shares of Kymera Therapeutics by 20.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after purchasing an additional 1,061,957 shares during the last quarter. Commodore Capital LP purchased a new position in shares of Kymera Therapeutics during the second quarter worth about $32,730,000. Alyeska Investment Group L.P. grew its holdings in shares of Kymera Therapeutics by 1,130.2% during the third quarter. Alyeska Investment Group L.P. now owns 615,091 shares of the company’s stock worth $34,814,000 after purchasing an additional 565,091 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Kymera Therapeutics by 121.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after purchasing an additional 491,737 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Kymera Therapeutics by 340.4% during the first quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock worth $13,972,000 after purchasing an additional 394,562 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.